Trial Profile
An Open Label Trial to Assess the Safety and Efficacy of Burosumab in a Single Patient With Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications Hypophosphataemia
- Focus Therapeutic Use
- 04 Mar 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 04 Mar 2022 Planned primary completion date changed from 30 Oct 2021 to 30 Oct 2022.
- 29 Jan 2021 Planned End Date changed from 1 Aug 2021 to 1 Mar 2022.